Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia (Q46697072)

24 December 2017

title

Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia (English)

1 reference

24 December 2017

author name string

Nandakumar Sambandam

1

1 reference

24 December 2017

Dominique Morabito

2

1 reference

24 December 2017

Cory Wagg

3

1 reference

24 December 2017

Brian N Finck

4

1 reference

24 December 2017

Daniel P Kelly

5

1 reference

24 December 2017

Gary D Lopaschuk

6

1 reference

24 December 2017

publication date

9 September 2005

1 reference

24 December 2017

American Journal of Physiology Heart and Circulatory Physiology

published in

1 reference

24 December 2017

volume

290

1 reference

24 December 2017

issue

1

1 reference

24 December 2017

page(s)

H87-95

1 reference

24 December 2017

Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

PPAR signaling in the control of cardiac energy metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

Hypoxia up-regulates expression of peroxisome proliferator-activated receptor gamma angiopoietin-related gene (PGAR) in cardiomyocytes: role of hypoxia inducible factor 1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

A role for peroxisome proliferator-activated receptor alpha (PPARalpha ) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated wi

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

Control of cardiac pyruvate dehydrogenase activity in peroxisome proliferator-activated receptor-alpha transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

Characterization of 5'AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

Regulation of fatty acid oxidation in the mammalian heart in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact Of Nicorandil on Angina. Combination Assessment of Ranolazine In Stable Angina. ENhancing Recovery In Coronary Heart Disease patien

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

Preconditioning and metabolic anti-ischaemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

PPAR-alpha activation required for decreased glucose uptake and increased susceptibility to injury during ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

Decrease in mitochondrial complex I activity in ischemic/reperfused rat heart: involvement of reactive oxygen species and cardiolipin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

beta-Hydroxybutyrate inhibits myocardial fatty acid oxidation in vivo independent of changes in malonyl-CoA content

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00285.2005

10.1152/AJPHEART.00285.2005

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

PubMed ID

16155108

1 reference

24 December 2017